MedTrace Logo

Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years

NCT02803944 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2055

Last updated 2016-06-17

No results posted yet for this study

Summary

Azithromycin is an antibiotic currently prescribed continuously in cystic fibrosis patients. It was shown that this treatment taken every day or every week for 12 months, can improve the respiratory state of patients. From the second year of treatment, it would appear there is more profit to continue such treatment.

The main objective is to study the association between continuous use of azithromycin and lung function measured by Forced expiratory volume in one second (FEV1), after two years of treatment.

Conditions

Interventions

DRUG

Azithromycin

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Isabelle DURIEU, Pr · Hospices Civils de Lyon - Centre Hospitalier Lyon Sud

Eligibility

Min Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02803944 on ClinicalTrials.gov